Supriya Peshin, Internal Medicine Resident Physician at Ballad Health, shared a post on LinkedIn about a paper she co-authored with colleagues:
“Publication Alert.
Targeted therapies are rapidly reshaping the landscape of NSCLC. This review breaks down the newest advances in KRAS inhibitors including beyond G12C along with updates in EGFR, ALK, MET, HER2, RET, ROS1, and FGFR-directed treatments. We also highlight emerging targets like TROP-2, offering a glimpse into the future of precision oncology in NSCLC.”
Title: Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
Authors: Supriya Peshin, Ehab Takrori, Joseph H. Yazji, Johum Haque, Adit Dharia, Mohammad Sajid Mithani, Fnu Anum, Ummul Asfeen, Jill Kristen Couch, Mabe Donovan, Sakshi Singal
More posts featuring Supriya Peshin on OncoDaily.